相关实验视频

Updated: May 30, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

在TAFRO综合征中,对葡萄糖皮质类药物初始治疗的反应以及对二次治疗的影响

Ryutaro Tominaga¹, Kento Umino¹, Seina Honda¹

¹Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

International journal of hematology

|January 29, 2025

概括

葡萄糖皮质激素 (GC) 治疗是TAFRO综合征的常见初始治疗方法. 这项研究发现,早期添加二线或脉冲疗法并没有改善存活率,但更高的严重性得分预测了GC耐药性.

科学领域:

血液学血液学血液学
内部医学内部医学
临床研究临床研究

背景情况:

塔弗罗综合征是一种罕见的全身性疾病,其特征是血小板缺血,阿纳斯卡,发烧,网球蛋白纤维化和有机巨变.
葡萄糖皮质类药物 (GC) 经常被用作初始治疗,但它们在超急性阶段的有效性和最佳使用仍在研究中.

研究的目的:

评估TAFRO综合征的各种初始治疗方法的治疗效果,其中包括葡萄糖皮质类药物 (GC).
确定与抗性GC治疗相关的因素,并评估早期干预对整体存活时间的影响.

主要方法:

追溯收集到2023年11月之前诊断的TAFRO综合征病例.
评估总生存期 (OS) 和GC治疗耐药性,以下一次治疗或死亡的时间 (TTNTD) 定义.
进行了多变量分析,以确定GC耐药性的预测因素.

主要成果:

在GC单一治疗和早期添加二线治疗 (86.6%vs77.7%) 之间没有观察到100天的OS显著差异.
同样,在2周内进行GC脉冲疗法,与没有脉冲疗法相比,100天的生存状况没有显著改善 (77.5%vs93.1%).
治疗前严重性得分≥8和血小板数≥6.9×10^4/μL与较短的TTNTD显著相关,表明潜在的GC耐药性.

结论:

早期添加二线或GC脉冲疗法似乎不会在TAFRO综合征的过敏阶段提供优势.
较高的治疗前严重性得分和血小板数量增加可能预测对初始葡萄糖皮质激素治疗的耐药性.
需要进一步的研究来优化TAFRO综合征的治疗策略,特别是对于高风险的GC耐药性患者.

关键词:

葡萄糖皮质类药物是什么免疫抑制剂是一种免疫抑制剂.多中心的卡斯特曼病多中心的卡斯特曼病.塔弗罗综合征 (TAFRO综合征) 是一种血小板减少症 (Thrombocytopenia) 是一个严重的疾病.

更多相关视频

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...